Page last updated: 2024-08-25

sofosbuvir and Cardiovascular Diseases

sofosbuvir has been researched along with Cardiovascular Diseases in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Biomy, R; Haseeb, WA; Maher, KA; Youssef, MM; Zaghloul, MS	1
Brainard, DM; Chung, RT; Doehle, B; Gustafson, J; Kim, AY; Lauer, GM; Liu, L; McHutchison, JG; Mo, H; Pang, PS; Simon, TG; Stamm, LM	1
Kohli, A; Kottilil, S; Masur, H; Meissner, EG; Osinusi, A; Remaley, AT; Sampson, M; Sidharthan, S; Tang, L; Townsend, K	1

Trials

1 trial(s) available for sofosbuvir and Cardiovascular Diseases

Article	Year
Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. AIDS research and human retroviruses, 2016, Volume: 32, Issue:5 Topics: Antiviral Agents; Benzimidazoles; Cardiovascular Diseases; Cholesterol, LDL; Coinfection; Drug Therapy, Combination; Dyslipidemias; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolines; Ribavirin; Sofosbuvir; Thiophenes; Uridine Monophosphate	2016

Article

Year

Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.

AIDS research and human retroviruses, 2016, Volume: 32, Issue:5

Topics: Antiviral Agents; Benzimidazoles; Cardiovascular Diseases; Cholesterol, LDL; Coinfection; Drug Therapy, Combination; Dyslipidemias; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolines; Ribavirin; Sofosbuvir; Thiophenes; Uridine Monophosphate

2016

Other Studies

2 other study(ies) available for sofosbuvir and Cardiovascular Diseases

Article	Year
Cardiovascular Risk Assessment After Sofosbuvir And Daclatasvir Regimen For Chronic Hepatitis C Virus Infection. JPMA. The Journal of the Pakistan Medical Association, 2023, Volume: 73(Suppl 4), Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Genotype; Heart Disease Risk Factors; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Pyrrolidines; Risk Factors; Sofosbuvir; Treatment Outcome	2023
The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease. Antiviral therapy, 2016, Volume: 21, Issue:3 Topics: Aged; Antiviral Agents; Benzimidazoles; Cardiovascular Diseases; Cross Infection; Disease Outbreaks; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir; Uridine Monophosphate	2016

Article

Year

Cardiovascular Risk Assessment After Sofosbuvir And Daclatasvir Regimen For Chronic Hepatitis C Virus Infection.

JPMA. The Journal of the Pakistan Medical Association, 2023, Volume: 73(Suppl 4), Issue:4

Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Genotype; Heart Disease Risk Factors; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Pyrrolidines; Risk Factors; Sofosbuvir; Treatment Outcome

2023

The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease.

Antiviral therapy, 2016, Volume: 21, Issue:3

Topics: Aged; Antiviral Agents; Benzimidazoles; Cardiovascular Diseases; Cross Infection; Disease Outbreaks; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir; Uridine Monophosphate

2016